Eledon Pharmaceuticals
ELDN
21 hedge funds and large institutions have $88.4M invested in Eledon Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 6 closing their positions.
397.84% more ownership
Funds ownership: 2.75% → 400.59% (+398%)
46% more capital invested
Capital invested by funds: $60.6M → $88.4M (+$27.8M)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
11% more funds holding
Funds holding: 19 → 21 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$17M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.97M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$180K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$22K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$19K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
ELDN Hedge Fund Activity: Q4 2020 in Review
21 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2020, worth a combined $88.4M — up 46% from $60.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ELDN positions and 6 closed out — a net gain of 2 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $27M. The largest seller was OrbiMed, cutting an estimated $1.97M.
- 21 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2020, up from 19 in Q3 2020.
- Funds reported $88.4M of Eledon Pharmaceuticals stock for Q4 2020, up 46% quarter-over-quarter.
- 8 funds opened new Eledon Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +2 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2020 was Cormorant Asset Management, an estimated $27M added.
- The largest Eledon Pharmaceuticals seller in Q4 2020 was OrbiMed, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2020.